Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3110 participants.

Also called NCT05485961

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose supportive care
Phase
Phase 2/3
Enrolled
  • 3,110 participants (planned count) (from the registry)
Sponsor
  • CSL Behring Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05485961
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05485961. Randomized; quadruple masking; primary purpose supportive care. Start 2024-04-27 (actual); primary completion 2029-05-22 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Acronym
POSIBIL6ESKD
Condition
End Stage Kidney Disease
Intervention (Drug)
CSL300
Intervention (Drug)
Placebo
Lead sponsor
CSL Behring (class: industry)

Record details

Record id
cardio:ct-nct05485961
Content hash
de423c8e78f1a189cbf6d1fd321eb974ee0af7cd147c64f9d915d7b2905fddca